Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
Joan Seoane Suarez, Barcelona (ES); Silvia Penuelas Prieto, Barcelona (ES); and José Baselga Torres, Barcelona (ES)
Assigned to Fundació Privada Institutció Catalana de Recerca I Estudis Avançats (ICREA), Barcelona (ES); Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO), Barcelona (ES); and Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron (IR-HUVH), Barcelona (ES)
Filed by Fundació Privada Institutció Catalana de Recerca I Estudis Avançats (ICREA), Barcelona (ES); Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO), Barcelona (ES); and Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron (IR-HUVH), Barcelona (ES)
Filed on Aug. 24, 2020, as Appl. No. 17/001,530.
Application 16/115,191 is a division of application No. 13/138,804, granted, now 10,100,112, issued on Oct. 16, 2018, previously published as PCT/EP2010/054499, filed on Apr. 6, 2010.
Application 17/001,530 is a continuation of application No. 16/115,191, filed on Aug. 28, 2018, abandoned.
Claims priority of application No. ES200900928 (ES), filed on Apr. 3, 2009.
Prior Publication US 2020/0385455 A1, Dec. 10, 2020
1. A method for treating glioma in a subject in need thereof, comprising administering a therapeutically effective amount of a neutralizing antibody that specifically binds leukemia inhibitory factor (LIF); wherein the antibody inhibits proliferation of tumor stem cells.